More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Both operations can help obese patients lose weight, researchers noted, but gastric bypass surgery "may be associated with greater cardiovascular benefits."
Patients often develop AFib during cardiac surgery, leading to longer hospital stays, additional healthcare costs and a higher risk of mortality. Cooling the oblique sinus of the patient's heart as soon as AFib starts to develop may represent a new way to stop the problem in its tracks.
Using one of the most powerful MRI scanners to date, researchers believe they have identified subtle neural changes in the brain that precede Parkinson’s disease.
